EMR

Emerson is a durable industrial-automation franchise, and FY2025 shows the quality: gross margin of 52.8% and net margin of 12.7% on $18.0B revenue, with diluted EPS up 17.8% to $4.04 and net income up 16.5% to $2.29B. The problem is that the top line barely moved — revenue grew just 3.0% — so most of the earnings gain came from margin and a 1.5% lower share count (buybacks more than doubled to $1.17B). At $150.66 the stock trades at 37.3x GAAP EPS and 4.7x sales while generating only an 11.3% return on equity. That is a premium multiple for low-single-digit growth and a middling ROE; the price already embeds a lot of execution.

The filing language reinforces caution. Management's MD&A leans heavily on a stack of non-GAAP measures — underlying sales, adjusted EBITA, adjusted EBITDA, adjusted EPS — explicitly built to strip out 'acquisitions or divestitures, amortization of intangibles, restructuring costs, discrete taxes, gains, losses and impairments.' That framing matters because GAAP results here are genuinely noisy: net income swung from $3.23B (FY2022) to $13.2B (FY2023, a divestiture-inflated figure) down to $1.97B (FY2024) before recovering to $2.29B (FY2025). The 37x headline P/E therefore overstates the multiple investors actually pay on adjusted earnings, but it also signals you can't take any single GAAP year at face value.